Stay Tuned!

Subscribe to our newsletter to get our newest articles instantly!

Tech News

Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting

  • Data show activity across a wide range of human tumor cell lines
  • Tumor regression observed in xenograft models of small cell lung cancer and ovarian cancer
  • Research from the laboratory of Dr. Matthew Oser at the Dana Farber Cancer Institute identified the key role of the SAC complex in selective tumor cell killing by cyclin A/B inhibitors


Circle Pharma announced today that two poster presentations at the American Association for Cancer…

Source link


Techy Nerd

About Author

Leave a comment

Your email address will not be published. Required fields are marked *

You may also like

Tech News

3 ways businesses can strike the ideal marketing and IT balance

We’re seeing two schools of thought emerge on how best to leverage data in the digital media landscape. The first
Software Tech News

Build Smart Biolinks with AI: Introducing the AI Biolink Creator

AI powered content for Bio Links and Marketing.